| Names | |
|---|---|
| Preferred IUPAC name | (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one |
| Other names | Zithromax Azithrocin Azithral Zmax Azee |
| Pronunciation | /əˌzɪθ.rəˈmaɪ.sɪn/ |
| Identifiers | |
| CAS Number | 83905-01-5 |
| Beilstein Reference | 3581247 |
| ChEBI | CHEBI:2955 |
| ChEMBL | CHEMBL1172 |
| ChemSpider | 21110929 |
| DrugBank | DB00207 |
| ECHA InfoCard | ECHA InfoCard: 100.059.414 |
| EC Number | EC 3.1.6.2 |
| Gmelin Reference | 108397 |
| KEGG | D07452 |
| MeSH | D000900 |
| PubChem CID | 447043 |
| RTECS number | QAN769J1PW |
| UNII | J2KLZ20U1M |
| Properties | |
| Chemical formula | C38H72N2O12 |
| Molar mass | 749.0 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.18 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 3.0 |
| Vapor pressure | 3.1E-30 mmHg |
| Acidity (pKa) | 8.74 |
| Basicity (pKb) | 7.34 |
| Magnetic susceptibility (χ) | -90.5×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.537 |
| Dipole moment | 2.52 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 322.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -11700 kJ/mol |
| Pharmacology | |
| ATC code | J01FA10 |
| Hazards | |
| Main hazards | May cause allergic reactions, liver dysfunction, gastrointestinal disturbances, and heart rhythm disorders. |
| GHS labelling | GHS05, GHS07, GHS08 |
| Pictograms | 💊⚠️🚫🤰🚼🍽️ |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| Flash point | 70 °C |
| Autoignition temperature | 270 °C |
| Lethal dose or concentration | LD50 (oral, rat): >2,000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Azithromycin: 2000 mg/kg (oral, rat) |
| NIOSH | Not Listed |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 500 mg once daily for 3 days |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Erythromycin Clarithromycin Roxithromycin Telithromycin Josamycin Dirithromycin |
| Parameter | Details | Manufacturer Commentary |
|---|---|---|
| Product Name | Azithromycin | In production, batches are labeled with product name and batch number for traceability during manufacturing, packaging, and shipment. Any process deviation references this identity for quality investigation. |
| IUPAC Name | (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one | Supplied on Certificate of Analysis and monograph documentation. Used to verify structural identity by QC through NMR and IR testing to rule out analogs or structural isomers. |
| Chemical Formula | C38H72N2O12 | Reflected on internal QC logs and shipping documents. Formula cross-checked with analytical data; correct ratio confirms production method integrity and absence of major synthetic deviations. |
| Synonyms & Trade Names | Azithromycin Dihydrate, Zithromax (trade name), Azithrocin, Sumamed, Zmax | Trade names appear in documentation for export labeling; generic synonyms are often requested by buyers for regulatory registrations and procurement. Only manufacturer-validated names are used on formal shipping documents. |
| HS Code & Customs Classification | 2941.90 | HS code assignment is aligned with current customs tariffs for macrolide antibiotics. Periodic consultations with customs compliance teams ensure code updates are reflected promptly to prevent border delays or reclassification. The precise code may slightly vary depending on regional interpretations of finished/pharmaceutical versus API intermediate. Documentation aligns with regulatory submission standards for both bulk-API and formulated forms, depending on customer requirements. |
During industrial synthesis, product labeling follows a tightly controlled system under GMP protocols. This ensures that all steps from raw material input, through in-process checks, to finished API meet traceability and verification protocols. Synonym and trade name referencing sometimes changes with new regional registrations, but the CAS registry number and IUPAC name remain the backbone of product authentication for analytical audits.
The chemical formula is confirmed in each batch by mass balance and by advanced analytical techniques—NMR and LC-MS outcomes are matched against the theoretical formula to confirm batch consistency. Deviation marks the need for root cause analysis; most such events stem from incomplete reaction or post-synthesis degradation.
Raw material selection for azithromycin focuses on macrolide ring integrity and minimal by-product risk. Route selection considers scalability, impurity profile, and solvent recovery feasibility. Impurity controls focus around starting material purity, catalyst removal efficiency, and tight temperature/time correlation in the key azalide ring-forming steps. Purification uses preparative chromatography or crystallization tailored to the impurity landscape in each production run.
HS code accuracy directly affects logistics and customs clearance lead time. Strong communication between regulatory affairs, logistics, and production teams helps minimize rework or risk of shipment holds due to misclassification, especially in large-scale or cross-border API trade.
For application-sensitive end users, grade-dependent requirements dictate batch release standards. These standards differ for API and formulated pharmaceutical uses, with additional microbiological testing mandated for direct-pharma grades. Each product grade may include tailored specifications, and any modifications must follow a documented change control process before implementation into active production orders.
Azithromycin is typically produced as a white or almost white crystalline powder. Visual and organoleptic properties such as color and odor often serve as batch-release indicators: color shifts can signal contamination or degradation and strong odors may suggest the presence of residual solvents. The powder’s flowability and particle size directly impact its handling during tableting or capsule filling.
The melting point profile, usually established via DSC or capillary analysis, shows batch variation based on residual moisture and crystalline form. Boiling and flash points hold limited technological relevance given azithromycin’s thermal sensitivity, but these parameters factor into safety protocols for solvent removal. Density is not usually a critical quality attribute, but its variations may affect volumetric dosing during granulation or blending.
Azithromycin’s lactone system and desosamine moiety are sensitive to acid and strong oxidizers. Batch instability usually traces back to trace acidity in process water, oxidative agents in the environment, or elevated thermal exposure during drying. Protective steps such as inert atmosphere handling and pH-buffered crystallization are implemented during downstream processing.
Solubility profile differs based on salt form and processing grade. Azithromycin is sparingly soluble in water, more soluble in alcohols. In formulation labs, dissolution is aided by mild heating and pH adjustment, though excessive heat can trigger degradation. Buffer selection impacts both solubility and impurity carryover—thus, solution preparation protocols depend on the analytical or formulation end-use.
Regulatory and customer-driven specifications define limits for assay, loss on drying, residual solvents, heavy metals, and organic impurities. Pharmaceutical-grade azithromycin targets higher purity and lower impurity thresholds versus veterinary or technical grades. Exact specification tables reflect registration dossiers or end-market regulations and evolve as monographs update.
Key impurity groups include related erythromycin congeners, desosaminyl byproducts, and epimers formed during synthesis. Typical values depend on synthesis route and purification stage. Impurity profiles must be regularly audited, as certain byproducts intensify under storage stress, and stringent customer requirements may dictate lower detection thresholds.
HPLC remains the mainstay for both assay and impurity profiling. Microbial testing, optical rotation, and water content measurements are also critical, with methods either compendial (USP, EP) or validated in-house. Testing frequency and batch-release criteria are set in alignment with product grade and geographic market.
Macrolide precursor selection weighs both purity and supply reliability. The main azithromycin precursor is erythromycin base, often sourced from fermentative routes. Procurement teams prioritize suppliers with traceable microbial source histories and minimal risk of cross-contamination. Solvent and reagent quality, especially for key alkylation and reduction steps, influences the impurity burden in the final product.
Industrial routes convert erythromycin base into azithromycin via Beckmann rearrangement or McCoy modification. Catalyst choices and solvent systems differ by plant infrastructure. Reaction atmosphere, pH control, and reaction time determine product yield and impurity levels. Entrainment of byproducts during cyclization or methylation often drives additional purification cycles.
Key control points include stoichiometry of reagents, reaction temperature ramping, and phase separation efficiency. In-process controls monitor intermediate conversion, residual solvents, and key byproduct evolution. Crystallization parameters affect final purity and particle size. Purification combines solvent washing, filtration, and occasionally chromatography, guided by impurity fingerprinting data.
Each batch undergoes multi-stage quality control: in-process monitoring, intermediate testing, and final product certification. Release testing targets defined assay ranges, impurity limits, and microbial contamination thresholds. The final release standard is subject to internal quality control criteria and customer requirements, with tighter limits for regulated markets.
Azithromycin’s reactive centers—mainly the lactone and the aminosugar—facilitate further modification for analog synthesis and specialized salt formation. Esterification and amidation represent common routes for prodrug development in R&D-focused manufacturing.
Most chemical modifications prefer mild basic or neutral conditions, as the core macrolide degrades under strong acid or heat. Catalyst selection and solvent compatibility must be balanced against product recovery and downstream purification needs. In practice, solvent recovery efficiency and achievable yields dictate process scalability.
Manufacturers commonly supply azithromycin hemihydrate or dihydrate forms, with salt forms and tailored derivatives delivered for contract synthesis. Each derivative may require separate crystallization parameters and impurity management strategies, linked both to end-use requirements and supply chain risks associated with individualized orders.
Azithromycin’s stability reflects sensitivity to humidity and heat. Desiccated storage in light-opaque containers at controlled room temperature is favored in production warehouses. For higher-activity grades, inert gas overlay or vacuum-sealed packaging can further limit hydrolytic and oxidative degradation.
Solid azithromycin is compatible with high-density polyethylene and glass, but solvents or formulations may require special linings due to reactivity or extractables concerns. Drum-seal integrity is regularly audited during storage and transportation, especially for batches with extended transit times or export clearance delays.
Typical shelf life is established via real-time stability studies and accelerated aging protocols, always grade- and formulation-specific. Degradation often presents as color darkening, odor development, and loss of potency. Re-test intervals and re-evaluation protocols sort out-of-window goods depending on final market and downstream sensitivity requirements.
Hazard classification reflects acute oral toxicity and potential skin or respiratory irritation from the bulk powder. Classification varies between jurisdictions and grade; full statements are defined in material safety data sheets in accordance with local regulations.
Routine handling calls for minimizing inhalational and dermal exposure. Closed-system transfer and dust collection equipment reduce occupational exposure risks. Typical PPE includes respiratory protection and chemical gloves during weighing, blending, and packaging.
Toxicological profiling in an industrial context centers on oral, dermal, and inhalational endpoints linked to manufacturing exposure. Non-clinical toxicity guidance for azithromycin comes from existing pharmaceutical dossiers, with special attention to operator sensitization and environmental discharge constraints.
Exposure control protocols in plant settings adhere to current occupational hygiene limits where established. Isolated handling areas, HEPA filtration, and containment systems are introduced for higher throughput lines or fine powder grades. Training and engineering controls serve as primary safeguards; reliance on PPE is considered a supplementary measure.
Capacity depends on process route, reactor allocation, and campaign scheduling. Multi-product pharmaceutical plants prioritize API lines based on regulatory, demand, and customer allocation. High purity azithromycin calls for additional purification cycles, which lengthen campaign times. Continuous-flow lines and automation help maintain consistent batch output during peak demand.
Production shifts to accommodate regional surveillance—emerging resistance, new regulatory filings, and import alerts in major economies such as the US and EU impact annual output planning. Spot shortages can arise when one or more markets issue special procurement tenders or when a major supplier’s line undergoes overhaul for plant audit upgrades.
Lead time fluctuates. Typical release cycles for standard-grade API batches run 3–6 weeks from confirmed order, factoring in in-process test results and final COA issuance. Specialty grades or tighter impurity controls may push lead times due to extended QC release and documentation. MOQ varies by grade: research-use only (RUO) and non-GMP may ship at low-volume, while USP/EP grade or licensed intermediates trigger larger batch MOQs, given campaign setup costs.
Bulk packaging aligns with grade and destination: drum-lined high-density PE for bulk pharma grade, double polyethylene-liners for GMP APIs, carton options for research-scale, all meeting respective ICH and local transport standards. For regulated markets, tamper-evident seals and serialized barcodes apply. Customer-specific labeling and dual-language COA accompany regulated shipments as required.
Preferred Incoterms reflect customer base. CIF and DAP terms predominate for US and EU buyers requiring compliant handling. FCA, EXW remain routine for domestic or non-pharma intermediates. Payment is subject to credit evaluation—30–60 day terms for established accounts in regulated markets, L/C or advance for new buyers or non-GMP inquiries. Bulk forwarding partners must meet local GDP standards to minimize temperature fluctuation during transit.
Macro-azalide synthesis routes select either semi-synthetic or fully synthetic azithromycin intermediates. Key raw materials—erythromycin base, key solvents (e.g., dichloromethane, acetone), and catalyst systems—determine core cost. Erythromycin volatility ties back to feedstock availability, weather impact on fermentation (for precursor antibiotics), and trading restrictions in dominant sourcing regions.
Feedstock price swings, downstream fermentation yields, and annual quota changes drive raw material cost cycles. Supply interruptions for erythromycin intermediates during plant closures (planned or due to regulatory action) result in immediate API price impact. Local environmental controls on emissions and disposal may spike costs for process solvents, with compliance often requiring multi-stage solvent recovery or carbon capture systems—costs passed through in invoice pricing.
API-grade, injectable-grade, and non-GMP research-grade pricing differ due to process stringency, documentation, batch tracking, impurity profiling, and validation costs. Injectable and export-quality grades demand comprehensive mass balance reports and residual solvent documentation, and incur higher quality assurance. As regulatory filings broaden, pharmaceutical buyers pay a premium for traceable lots with complete ICH Q7 GMP support.
Packaging cost jumps with double-barrier systems, serialized labeling, or cold-chain support. Certified batches with accompanying DMFs or CEP documentation reflect the overhead for maintenance, regular audits, and mandatory disclosure filings, leading to structured, tiered pricing.
Global supply remains concentrated among large-scale API producers in China and India, due to scale economies and experienced regulatory compliance management. Regulation shifts, such as import restrictions and preferences for domestic supply in the US/Europe/Japan, have caused periodic regional shortages or escalated delivered cost.
US and EU buyers maintain rigorous import surveillance, periodic supplier audits, and persistent pricing pressure. US FDA and EMA filings require traceable GMP batch and stability data. Indian manufacturers adopt integrated production to buffer against feedstock import taxes, offsetting cost with backward integration. In China, regulatory upgrades since 2018 have raised compliance bar but supply cost advantages persist. Japanese procurement focuses on high-certification imports, with batch-specific retesting.
Industry projection leans toward moderate price elevation by 2026 as regulatory scrutiny tightens, emission standards rise in core production regions, and the cost of compliance continues to escalate. Fluctuations in macrolide precursor pricing and tightening environmental standards in major producer countries create cost pass-through pressure, predicted to manifest in 3–8% annualized increases for top-grade API.
Price trend analysis is based on internal procurement tracking, market participant consultations, quarterly regulatory updates, and batch-by-batch tender histories in major economies.
Stringent audit regimes in Europe and the US continue to filter out API suppliers lacking comprehensive data integrity or full-chain traceability. Temporary plant shutdowns for environmental upgrades have tightened supply in the past two years. Some suppliers have exited the market rather than retrofit for new standards.
Regulators have advanced expectations for nitrosamine impurities and data transparency. Increased global harmonization on impurity reporting continues to impact release practices for API. Revised ICH M7 adoption targets even lower threshold impurities, leading to extended in-process and release testing.
Producers have accelerated implementation of online batch tracking, AI-based impurity prediction, and real-time process surveillance to anticipate and eliminate noncompliance risk. Internal audit frequency increased to align with US/EU standards and minimize recall risks. Investment in closed-loop solvent recovery and green process adaptation is ongoing, balancing regulatory cost with batch consistency and yield.
Azithromycin production focuses on pharmaceutical ingredients for oral and injectable formulations. Downstream users include branded and generic drug manufacturers, hospital formulary suppliers, and formulation sites registered with global regulatory agencies. Beyond human pharmaceuticals, veterinary use plays a role in some regions, with strict attention paid to antimicrobials regulation and allowable residue limits.
Most demand centers on finished dosage manufacturing, including tablets, suspensions, and injectable powders. Custom requirements arise for contract development and manufacturing organizations (CDMOs), especially when matching process contaminants and impurity control to customer pharmacopoeial or regulatory filings.
| Target Application | Recommended Grade(s) | Notes on Critical Parameters |
|---|---|---|
| Pharmaceutical API (oral, solid) | USP/EP/JP/ChP grades | Purity, residual solvents, heavy metal profile, microbial limits adjusted per target market dossier |
| Pharmaceutical API (injectable) | Injectable/Parenteral grade | Tighter limits on endotoxins, solvents, particulate matter, validated sterile handling |
| Veterinary drug use | Veterinary grade/API | Compliance with country-specific MRLs and guidelines, some variability in impurity and residual solvent thresholds |
| R&D/preclinical use | Research/Technical grade | Process impurities, solvents, and microbial control less stringent; not suitable for human/animal administration |
Across applications, assay and impurity profile differences define grade boundaries. Injectable use always draws the sharpest impurity and pyrogen targets, with batch release control for particulate and endotoxin burden. Regulatory-driven releases (USP, EP, ChP, JP) fix assay and related substance maxima; internal control may extend further, depending on customer technical agreements.
Functional properties like polymorphic form, particle size distribution, and flow depend on dosage form manufacture. Suspension and powder fillers assign tighter constraints on these than tablet compacting. Veterinary APIs occasionally use wider impurity or particle size windows, varying by region and local regulation.
Starting from the end-use, the routings for azithromycin split early: solid, suspension, and injectable lines run under distinct property and impurity control regimes. Every project in pharma—human or animal—requires precise matching of quality grade to its registration and submission track.
Origin country for finished product registration sets the expected compendial monograph. Matching to USP, EP, ChP, or JP can move the reference specification, even as core points overlap. Injectable products prompt close review of pharmacopoeial and agency-defined impurity, pyrogen, and solvent controls.
Tablet and suspension applications prioritize overall assay, organic impurity, and residual solvent profiles. Injectable grades force lower maxima for elemental and organic impurities and contribute more direct environmental controls during synthesis and packaging. Excessive control over attributes not relevant to the application drives up costs or limits synthetic yield unnecessarily.
Higher regulatory control and additional batch documentation influence batch cost and minimum order volume. Full parenteral validation—especially sterility and endotoxin controls—raises cost per batch. For internal R&D, technical or research grades offer volume pricing advantages when testing process scale-up, provided material is not used in humans or food-producing animals.
Onsite validation of selected azithromycin batch remains standard for qualifying a manufacturer’s material into finished dosage manufacturing. Usual practice includes analytical matching for impurity pattern, flow properties, and processability under the end formulator’s normal conditions. Enrollment into existing technical agreements or master file / DMF referencing streamlines downstream validation.
Production of Azithromycin maintains robust quality management systems. Manufacturing facilities operate under comprehensive standards such as ISO quality system certification. Internal audit teams routinely verify documentation, environmental controls, and personnel training. These programs address traceability, deviation management, and continuous improvement. Regulatory audits by external agencies add additional oversight depending on product destination and use requirements.
Certifications specific to Azithromycin often include pharmacopoeia compliance (such as USP or EP) and, where applicable, product registrations or DMFs. Registration status may depend on supply chain geography and downstream application, so supporting documents reference only qualifying batches and registered production lines. Batch release proceeds only after multi-stage internal review alongside targeted impurity profiling and microbiological testing. Pharmacopeial compliance hinges on targeted synthesis steps and purification effectiveness, with additional scrutiny on genotoxic impurities and process byproducts.
Each batch ships with qualifying documentation, including Certificates of Analysis, validated by internal quality assurance specialists. Technical documents reflect actual in-process controls and lot-specific assay results. Where required by the customer, full traceability dossiers covering raw materials, analytical protocols, and deviation investigations can be provided. For regulated markets or custom specifications, extended regulatory documentation—stability data, impurity profiles, and validation summaries—is available in accordance with customer QA agreements and legal requirements.
Azithromycin large-scale production draws from modular plant design and parallel reactor capacity. This approach supplies pharmaceutical manufacturers and formulators with buffer stocks during demand surges. Production flexibility adapts to customer forecasts and long-term supply schedules, supporting blanket orders or just-in-time delivery models. Ongoing investment in core process equipment and intermediate inventory management forms the backbone of stable supply scenarios.
The facility routinely reviews production runs to align with quality consistency and downstream requirements. Sourcing specialists monitor primary raw material quality, placing priority on critical reagent supply stability. In-process controls narrow process variability, and batch record systems document every key production, filtration, and purification step. Strategic warehousing supports direct shipment or regional stockholding, reducing dependency on any single logistics route.
Sample requests receive technical assessment from both the production and quality teams to confirm suitability with the intended application. The process includes evaluation of formulation requirements, regulatory grade, and handling needs. Whenever requested, supply of pre-shipment and development batches includes detailed analytical reports, giving downstream partners confidence in batch comparability and route-specific impurity trends.
Flexibility in supply contracts accommodates changes in order size, shipment frequency, and specification details. Customers may select fixed-schedule deliveries or dynamically adjust order size based on market demand. Collaboration can cover exclusive production for proprietary formulation needs or non-exclusive supply to support differentiated product lines. Forward integration with customer planning teams helps minimize lead time risks and supports rapid response to regulatory changes or formulation shifts. Change control systems ensure that specification, process, or packaging modifications run through joint customer-manufacturer review before implementation.
R&D attention remains focused on refining synthesis pathways to address impurity profiling and process economy. Hydrogenolysis and selective methylation steps continue to present significant cost and yield bottlenecks, especially for manufacturers aiming to comply with increasingly strict impurity specifications. Technical teams monitor emerging macrolide analogs with improved pharmacokinetics as competitors, pushing for route innovation, especially in regioselective reactions and chiral control.
Pediatric formulations, long-acting injectables, and variable-dose regimens have gained attention from both regulatory and commercial sides. Demand in veterinary sectors and certain niche APIs using azithromycin as a precursor shows steady inquiry volume, especially in markets emphasizing One Health approaches. Any new application is evaluated for solvent compatibility, micro-contaminant carryover, and the risk of cross-reactivity with excipient choices.
Yield drift during scale up continues to drive plant-level process improvement projects, with particular focus on the work-up and purification stages. Detectable levels of 3-epimers and azithromycin N-oxides challenge both analytical and preparative methods, with batch-to-batch reproducibility affecting final release profiles. CSR teams collaborate closely with process chemists to apply real-time monitoring for intermediate isolation to limit critical impurity formation. Breakthroughs in solid phase extraction and greener crystallization continue to be piloted to address solvent burden and reduce discharge loads.
Global volumes track rising with sustained pediatric and generic markets, yet regional regulatory tightening raises entry barriers. Pricing pressure and intermediate supply chain volatility, especially on the 9a-aza group precursors, add complexity for volume commitments on fixed-term contracts. Production allocation may need periodic adjustment to match downstream portfolio margins, especially as new APIs using azithromycin scaffolds enter early-phase pipelines.
Route optimization efforts target the steps most responsible for residual solvent load and impurity carryover. The transition to closed-containment and continuous flow processing sees pilot application for azithromycin intermediates, though scale economics still restrict widespread adoption. Chiral resolution and green catalysis remain under review, especially with geographies moving to stricter green chemistry requirements for antibiotic intermediates. Regional batch-tracking and end-to-end digitized lot records now supplement legacy paper trails for critical quality attributes (CQAs).
Synergy between waste minimization and chemical route redesign forms a core improvement mandate. Process engineers prioritize solvent recovery rates and minimize high-boiling point residues. Pollution control pivots to API-specific chemical oxygen demand (COD) and total organic carbon (TOC) targets, especially in high-throughput plants. Where customer specifications permit, new manufacturing routes with reduced intermediate isolation points undergo commercial scale validation to minimize both resource consumption and operator exposure. Ongoing evaluation looks at biotransformation steps and hybrid chemo-enzymatic processes for long-term reduction in process mass intensity (PMI).
Technical support teams provide direct consultation on impurity profiling, solvent system compatibility, and process up-scaling. Customers receive advice tailored to their grade-specific requirements, and specific questions on analytical method validation and regulatory submission data are addressed with technical reference samples upon request. Engineers also advise on raw material suitability for co-formulation, highlighting any at-risk functional groups or matrix interactions observed in ongoing manufacturing batches.
Support engineers engage with formulators and process scale-up teams to troubleshoot blending, granulation, or solvent dispersion issues observed in customer operations. Real-world batch deviation reports contribute to a running database used to inform future client consultations. Recommendations draw on proprietary process know-how and field performance feedback, targeting both generic large-volume and custom application-specific grade requirements.
Customers receive batch-specific quality documentation, including analytical certificates tied to internal release specifications reflecting both in-process and final product CQAs. Ongoing change notification protocols ensure all process shifts and raw material changes are disclosed as per customer and regulatory expectations. Post-sale, field observations drive root cause analysis and corrective action, focusing both on product performance and potential downstream process interactions, with regular review of claims to ensure rapid, data-driven resolution or replacement when quality triggers arise.
As a direct producer of azithromycin, we recognize the essential part this macrolide antibiotic plays in modern pharmaceutical synthesis. Our operations focus on consistent, large-scale manufacturing to supply businesses with the active pharmaceutical ingredient required for finished dosage forms. Over the years, our investment in proprietary process development and raw material sourcing has strengthened our position as a dependable partner for pharmaceutical formulators and industrial buyers.
All azithromycin batches reach completion at our own facilities. Each stage—from fermentation and extraction to purification and crystallization—runs under strict internal protocols. Our technical team adjusts key process parameters using proprietary controls to keep impurity levels tightly regulated. Real-time analytics support routine checks, limiting batch-to-batch variation in assay and particle attributes. Every lot receives full certification based on analytical data generated by our in-house laboratories, equipped with advanced instrumentation for quantitative and qualitative verification.
Industrial customers rely on azithromycin as a core input for solid and liquid formulations produced on commercial lines. Major applications include the synthesis of oral tablets, suspensions, and injectable solutions. The chemical structure of our product yields the consistent stability and solubility crucial to formulation scientists during scale-up. Large-scale pharmaceutical plants and contract manufacturers draw value from a dependable source with predictable supply and technical support, allowing seamless integration with downstream manufacturing operations.
Quality assurance covers more than just release testing. Continuous monitoring tracks both process and quality parameters across every production line, ensuring each lot meets industry standards for residual solvents, heavy metals, and microbial contamination. All analytical methods undergo regular method transfer validation, supporting robust and reproducible results with audit trails available for external inspection. Our certifications and documentation stand up to scrutiny from regulatory and quality assurance teams at global pharmaceutical firms.
We manage packaging in-house, using high-barrier materials to maintain stability over extended storage and transport. Custom packaging options meet specific plant logistics and handling needs—drums, fiberboard containers, or lined bags selected based on volume and shipping conditions. Our scale allows us to support just-in-time deliveries and large-scale campaigns, helping procurement teams manage inventory and production schedules with reduced risk of supply disruption. Distribution networks serve clients from centralized logistics hubs, minimizing lead times across cross-border and domestic shipments.
Process engineering and formulation teams engage directly with our technical staff. Support extends through technical documentation, process audit assistance, and analytical troubleshooting. When industrial partners face questions on solubility, stability, or cross-compatibility, our scientists offer data-driven answers grounded in direct production experience—streamlining product integration for formulation teams operating at commercial scale.
Manufacturers and procurement professionals require a production partner who maintains process transparency, controls delivery timelines, and stands behind technical claims. Direct link to manufacturing brings confidence in quality and addresses the operational realities faced by pharmaceutical and animal health customers managing high-volume production cycles. Risk mitigation for supply chains originates in stable process control, robust packaging, and rapid response technical teams—each managed by a producer with firsthand accountability.
Industrial clients investing in azithromycin supply seek more than product access—they need process certainty, technical knowledge, and commercial continuity delivered by the factory making the product. Our experience and scale in direct manufacturing establish a supply chain that keeps industrial formulators competitive and better equipped to respond to evolving market needs with minimal disruption.
In our chemical manufacturing plants, we oversee each batch of Azithromycin from start to finish. The stability profile of this antibiotic has been studied in-depth under a variety of environmental conditions, since the molecular structure depends on certain specific storage parameters to retain optimum quality through the product lifecycle.
Based on our experience in GMP environments, Azithromycin bulk material holds maximum chemical stability between 15°C and 30°C. Heat and moisture take a measurable toll on macrolide antibiotics. We monitor storage rooms with calibrated data loggers, because deviations outside this range increase the risk of degradation. At high temperatures, impurity profiles shift. Moisture triggers hydrolysis, especially when packaging barriers are breached or ambient relative humidity exceeds standard limits.
Our technical team tracks each lot post-production, using stability studies as part of routine quality operations. We record how product exposed to 40°C or direct sunlight—even for days—can develop discoloration and drop in assay values. Material integrity remains highest when kept away from heat sources and high humidity areas. Regular inspection of our storage facility, with tightly controlled ventilation and insulation, helps to reliably maintain this 15°C to 30°C window.
To reinforce temperature control, our standard packaging uses tightly sealed, multi-layer liners. We select materials that hold up to international transit and regional climate swings. Solid barrier systems, such as high-density polyethylene drums with moisture-proof liners, reduce air exchange, helping to keep humidity at bay during long-term storage. A temperature indicator label on each drum gives a visual alert if the package experiences excursions. These steps are built into our shipping and warehouse protocols for every customer delivery.
Clients in the pharmaceutical industry depend on consistent assay values and low impurity content in every shipment. The only way to meet these requirements is through vigilant temperature management at every stage—before the product reaches any formulation site. Handling material at 20°C to 25°C is well within the optimal parameters, aligning with WHO and pharmacopeial observations for many macrolides. Extended exposure above 30°C, especially during summer shipping or non-air-conditioned storage, requires swift corrective action to prevent quality loss.
Once our Azithromycin leaves the warehouse, each container includes explicit guidance: avoid unshaded or unventilated spaces, and minimize ambient temperature extremes during storage and transit. Our technical officers audit distribution channels regularly to confirm these measures stay in force.
With every strengthening in regulatory oversight, our factory invests in updated stability protocols and more advanced monitoring technology. New climate-controlled storage expands our buffer against global temperature fluctuations. Future plans include installing automated alarm systems tied to temperature breaches, further securing each lot’s compliance with agreed specifications.
Long-term reliability only comes from treating storage as a critical control point, not just a routine logistics check. We approach every batch as the next therapy for a patient, demanding careful attention from the first kilogram to the last pack on the pallet.
As a direct manufacturer, every batch of Azithromycin leaves our facility with a deep awareness of both production realities and market expectations. Buying in bulk means more than just a cost advantage—it puts our customers closer to the manufacturing process, more in control of planning, and less at the mercy of unpredictable supply chains.
We base our minimum order quantity—often abbreviated as MOQ—on batch size efficiency and regulatory compliance. Production runs follow stringent quality management protocols. Smaller orders disrupt validated procedures, increase per-unit cost, and complicate traceability. For Azithromycin, our MOQ is set with these factors in mind. Shipping less than a full batch means additional regulatory steps and a less predictable cost structure. By establishing a clear MOQ, we keep manufacturing streamlined and ensure the highest standard of quality is met at all times.
For customers in the pharmaceutical, veterinary, or contract manufacturing sectors, MOQ typically falls at the lower tonnage scale for the active ingredient. This aligns with both international and local compliance needs while making raw material supply manageable for everyone from formulation labs to large-scale production plants. Customers looking for anything below this threshold often encounter longer prep times or increased costs, which is why we keep a clear MOQ policy.
Lead time is an idea that becomes quite tangible in a manufacturing environment. Each order must navigate a series of steps—raw material procurement, API synthesis, in-process and final QC, packaging, and regulatory release. Our azithromycin line operates with a lead time that considers not just production but proper documentation and release testing. We understand the pressures downstream partners face, especially with timelines tied to formulation production or global tenders. We plan our production calendar quarterly, making it possible for regular customers to enjoy shorter lead times after initial onboarding and documentation. Unexpected disruptions, such as supply interruptions for key starting materials or unplanned inspections, can occasionally add a few days, but transparency remains our core value.
Bulk orders receive primary packaging suitable for extended storage and secure transport—typically high-density fiber drums with multiple inner linings, labeled with batch specifics and compliant with regional transport guidelines. We use packaging calibrated to minimize contamination risk and preserve product quality across long distances. Technical documentation, including Certificates of Analysis and DMFs, follows every shipment, supporting end-use registration and process validation.
Communicating MOQ and lead time right up front saves time for everyone—procurement teams, logistics coordinators, and ultimately, patients who depend on reliable antibiotic supply. Over decades, we have developed supply chain models built around clear commitments and direct communication. Customers with recurring needs often join our production calendar, which can lock in preferred lead times and remove much of the uncertainty from their planning processes.
We regularly invest in expanding upstream chemical capacity and automating packaging lines so our partners can count on robust inventory pipelines. Our technical team answers detailed questions about production, packaging, or quality control, often leading to supply solutions tailored for specific needs. We believe a clear MOQ, reliable lead time, and open communication keep operations smooth across the whole chain, from our reactors to your formulation tanks.
Global demand for azithromycin as an API and finished formulation keeps rising as healthcare systems rely on it for bacterial infection treatment. As the direct manufacturer, we take responsibility not only for producing a high-purity product but also for ensuring precise and transparent international delivery procedures. Exporting azithromycin across borders triggers a host of regulatory requirements, each dictated by national policies around pharmaceutical importation, public health, and controlled substances legislation.
No country treats antibiotics as a general commodity. Azithromycin falls under controlled categorization in most jurisdictions due to its pharmaceutical grade and use in human health. Our shipments always require health authority registration at the destination. Customs authorities nearly always request an export license from our side and an import license from the recipient's relevant government agency, often the Ministry or Department of Health. For many countries, there is no allowance for shipment without this paperwork.
We prepare each export shipment dossier with a complete Certificate of Analysis, Certificate of Origin, and full batch release data. Depending on the end market, the recipient often presents an Import Drug License, Product Registration Certificate (sometimes called Marketing Authorization), and in some regions, an import permit specific to each consignment. These forms stand as non-negotiable demands for border clearance. Any omission can mean detainment or destruction at port. For every delivery of azithromycin, we work with regulatory specialists familiar with the target country's current rules so we avoid compliance gaps.
Azithromycin isn’t regulated just for commercial purposes—it faces controls to combat antibiotic resistance and to prevent medication misuse. Many national authorities require an End-Use Statement and, in select markets, limits on annual import volume based on national need projections. We comply with such stewardship protocols as a matter of corporate policy and public health responsibility. Restrictions often increase in times of epidemic or pandemic response, with government or UN agencies tightening requirements as needed.
As a pharmaceutical manufacturer holding Drug Master Files and certifications for cGMP compliance, our quality documentation supports every delivery. Product traceability begins in production and follows through to export customs. Our technical team routinely provides real-time regulatory support, whether for clarifying material specification or for completing custom import forms mandated in various regions: EU, US, Southeast Asia, or Africa. We list our active ingredients with all major regulatory bodies and promptly support due diligence reviews as requested.
Documentation and licensing requirements evolve, especially with APIs like azithromycin subject to global vigilance. Over the past years, we have invested in in-house regulatory compliance functions, so we can maintain constant communication with consulates and health authorities for documentation updates. Our logistics division collaborates directly with freight forwarders who specialize in pharmaceuticals, reducing the risk of clearance delays. If clients require customized shipments for clinical trials or local repacking, we produce supporting paperwork in-house following validated procedures.
In summary, international deliveries of azithromycin call for thorough attention to regulatory detail, proactive dossier preparation, and deep knowledge of target market controls. As the manufacturer, we treat these obligations as integral to business, quality assurance, and partnership with global healthcare providers.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
